BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Rating Reaffirmed by HC Wainwright

HC Wainwright reissued their buy rating on shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) in a report released on Tuesday, Benzinga reports. They currently have a $30.00 price target on the biotechnology company’s stock.

Separately, Needham & Company LLC reiterated a buy rating and issued a $12.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Wednesday, April 10th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, BioCryst Pharmaceuticals presently has an average rating of Moderate Buy and a consensus target price of $14.00.

BioCryst Pharmaceuticals Stock Down 0.2 %

Shares of BioCryst Pharmaceuticals stock opened at $5.26 on Tuesday. The firm has a market cap of $1.09 billion, a price-to-earnings ratio of -4.46 and a beta of 1.96. BioCryst Pharmaceuticals has a 52-week low of $4.03 and a 52-week high of $8.96. The company’s 50-day simple moving average is $4.90 and its 200-day simple moving average is $5.45.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its earnings results on Monday, May 6th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.06. The business had revenue of $92.80 million for the quarter, compared to analysts’ expectations of $85.62 million. The business’s quarterly revenue was up 34.9% on a year-over-year basis. During the same period last year, the company posted ($0.28) earnings per share. Equities research analysts anticipate that BioCryst Pharmaceuticals will post -0.69 EPS for the current year.

Institutional Trading of BioCryst Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the company. Fifth Third Bancorp raised its stake in shares of BioCryst Pharmaceuticals by 17,500.0% during the 3rd quarter. Fifth Third Bancorp now owns 3,520 shares of the biotechnology company’s stock worth $25,000 after buying an additional 3,500 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in BioCryst Pharmaceuticals by 96.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 4,865 shares of the biotechnology company’s stock valued at $34,000 after acquiring an additional 2,388 shares in the last quarter. Quarry LP acquired a new position in BioCryst Pharmaceuticals during the fourth quarter worth about $54,000. Tower Research Capital LLC TRC raised its position in BioCryst Pharmaceuticals by 131.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 10,420 shares of the biotechnology company’s stock worth $62,000 after acquiring an additional 5,912 shares during the last quarter. Finally, JGP Global Gestao de Recursos Ltda. purchased a new stake in shares of BioCryst Pharmaceuticals in the fourth quarter valued at about $64,000. 85.88% of the stock is currently owned by hedge funds and other institutional investors.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.